How To Be Prepared For A Catastrophic Data Breach
Executive Summary
Pharmaceutical companies will be directly affected by the EU’s General Data Protection Regulation because they often hold large amounts of personal health information, such as clinical trial data, and any accidental disclosure of those data will be taken very seriously by the regulatory authorities. Richard Dickinson, Jacqueline Mulryne and Zoe Walkinshaw look at what companies should be doing to limit the impact of a catastrophic data breach on their corporate reputation, the individuals affected, and the validity of the data.
You may also be interested in...
How To Deal With A Dawn Raid By Competition Authorities
Pharmaceutical firms in Europe are increasingly the target of dawn raids by enforcement authorities in search of evidence of anti-competitive behavior. As John Schmidt and Will Mudge explain, such raids can be highly disruptive and distressing, and companies need to ensure they have robust processes and training in place so that staff can respond appropriately if government agents arrive at their offices unannounced.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.